Decitabine + Ustekinumab Interaction
Moderateinteraction on record
Description
Immunomodulator used concomitantly in approximately 30% of CD/UC subjects; safety and efficacy not adversely affected by combination.
Source: NLP:ustekinumab
Immunomodulator used concomitantly in approximately 30% of CD/UC subjects; safety and efficacy not adversely affected by combination.
Source: NLP:ustekinumab